CSIMarket


Biogen Inc   (BIIB)
Other Ticker:  
 

Biogen Inc

BIIB's Fundamental analysis








Biogen Inc 's sales fell by -7 % in I. Quarter 2024 from the same quarter a year ago. Ranking at No. 2120

Biotechnology & Pharmaceuticals industry recorded deterioration of revenues by -0.98 %

Biogen Inc 's net income grew by 1.5 % in I. Quarter 2024 year on year, above company average,

More on BIIB's Growth


Biogen Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Biogen Inc realized cash outflow of $ -12.45per share in trailing twelve-month period.
Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months.
Company
28.2
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 3.41.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.64.


More on BIIB's Valuation
 
 Total Debt (Millions $) 6,540
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 1,005,525
 Net Income/Employee (TTM) $ 121,467
 Receivable Turnover (TTM) 5.74
 Tangible Book Value (Per Share $) 4.80

Biogen Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Biogen Inc realized cash outflow of $ -12.45per share in trailing twelve-month period.
Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months.
Company
28.2
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 3.41.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.64.

Biogen Inc Price to Book Ratio is at 2.16 lower than Indusry Avg. of 751.04. and higher than S&P 500 Avg. of 0.01

More on BIIB's Valuation

  Market Capitalization (Millions $) 32,909
  Shares Outstanding (Millions) 146
  Employees 9,610
  Revenues (TTM) (Millions $) 9,663
  Net Income (TTM) (Millions $) 1,167
  Cash Flow (TTM) (Millions $) -1,816
  Capital Exp. (TTM) (Millions $) -361
  Total Debt (Millions $) 6,540
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ 1,005,525
  Net Income/Employee(TTM) $ 121,467
  Receivable Turnover Ratio (TTM) 5.74
  Tangible Book Value (Per Share $) 4.80

  Market Capitalization (Millions $) 32,909
  Shares Outstanding (Millions) 146
  Employees 9,610
  Revenues (TTM) (Millions $) 9,663
  Net Income (TTM) (Millions $) 1,167
  Cash Flow (TTM) (Millions $) -1,816
  Capital Exp. (TTM) (Millions $) -361


    BIIB's Profitability Comparisons
Biogen Inc achieved increase in profitability, decrease in demand. Operating Margin grew in I. Quarter 2024 to 24.38 % from 24.21 % in IV. Quarter.

Biogen Inc net profit margin of 17.18 % is currently ranking no. 7 in Biotechnology & Pharmaceuticals industry, ranking no. 53 in Healthcare sector and number 687 in S&P 500.


Profitability by Segment



  Ratio
   Capital Ratio (MRQ) 2.1
  Total Debt to Equity (MRQ) 0.43
  Tangible Leverage Ratio (MRQ) 16.2
  Asset Turnover Ratio (TTM) 0.37
  Inventory Turnover Ratio (TTM) 1.03



Biogen Inc achieved increase in profitability, decrease in demand. Operating Margin grew in I. Quarter 2024 to 24.38 % from 24.21 % in IV. Quarter.

Biogen Inc net profit margin of 17.18 % is currently ranking no. 7 in Biotechnology & Pharmaceuticals industry, ranking no. 53 in Healthcare sector and number 687 in S&P 500.

More on BIIB's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com